U.S. FDA Approves Olysio (Simeprevir) for Hepatitis C Treatment
November 25, 2013
This article was reported by the Science World Report.
An article in the Science World Report stated that the US Food and Drug Administration (FDA) on November 22 approved Olysio (simeprevir), a protease inhibitor that blocked a key hepatitis C protein from multiplying and would be part of a combination therapy with peginterferon-alfa and ribavirin. The treatment would be for hepatitis-C infected adults with diseased but functioning livers; people with cirrhosis; people who had not received any hepatitis C treatment (naï¿½ve patients); and those who had received previous unsuccessful treatments.View Full Article
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)